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Abstract Objective: Preliminary
assessment of an automated weaning
system (SmartCareTM/PS) compared
to usual management of weaning
from mechanical ventilation per-
formed in the absence of formal
protocols. Design and setting: A
randomised, controlled pilot study in
one Australian intensive care unit.
Patients: A total of 102 patients
were equally divided between
SmartCare/PS and Control. Interven-
tions: The automated system
titrated pressure support, conducted a
spontaneous breathing trial and pro-
vided notification of success
(‘‘separation potential’’). Measure-
ments and results: The median time
from the first identified point of suit-
ability for weaning commencement to
the state of ‘‘separation potential’’
using SmartCare/PS was 20 h (inter-
quartile range, IQR, 2–40) compared
to 8 h (IQR 2–43) with Control (log-
rank P = 0.3). The median time to
successful extubation was 43 h (IQR
6–169) using SmartCare/PS and 40
(14–87) with Control (log-rank
P = 0.6). Unadjusted, the estimated
probability of reaching ‘‘separation
potential’’ was 21% lower (95% CI,
48% lower to 20% greater) with
SmartCare/PS compared to Control.
Adjusted for other covariates (age,
gender, APACHE II, SOFAmax,
neuromuscular blockade, corticoste-
roids, coma and elevated blood
glucose), these estimates were 31%
lower (95% CI, 56% lower to 9%
greater) with SmartCare/PS. The
study groups showed comparable
rates of reintubation, non-invasive
ventilation post-extubation, tracheos-
tomy, sedation, neuromuscular
blockade and use of corticosteroids.
Conclusions: Substantial reductions
in weaning duration previously dem-
onstrated were not confirmed when
the SmartCare/PS system was com-
pared to weaning managed by
experienced critical care specialty
nurses, using a 1:1 nurse-to-patient
ratio. The effect of SmartCare/PS
may be influenced by the local clini-
cal organisational context.
Descriptor: 28. Mechanical venti-
lation: weaning.
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Introduction
Automated computerised systems for ventilatory man-
agement may provide improved adaptation of ventilatory
support through continuous monitoring and real-time
intervention [1]. The use of one such commercially
available automated weaning system (SmartCareTM/PS,
Dra¨ger Medical, Lu¨beck, Germany) was associated with a
substantial reduction in the duration of ventilation and
intensive care unit (ICU) length of stay when compared to
physician-controlled weaning using local guidelines in
five European ICUs [2].
SmartCare/PS monitors the patient’s respiratory status
every 2 or 5 min [frequency, tidal volume, (VT) and end-
tidal carbon dioxide (etCO2) concentration] and periodi-
cally adapts pressure support (PS) aiming for a safe,
efficient weaning process [1, 3]. The computerised
SmartCare/PS system establishes a respiratory status
diagnosis, determines an intervention and then instructs
the ventilator to decrease or increase PS, or leave it
unchanged to maintain the patient in a defined ‘‘respira-
tory zone of comfort’’ [4, 5]. Once SmartCare/PS has
successfully minimised the level of PS, an observation
period occurs, which may be followed by a recommen-
dation to ‘‘consider separation’’ (proceed if clinically
indicated to patient extubation).
The demonstrated ability of SmartCare/PS to reduce
the duration of weaning and ventilation may vary
according to local weaning practices and ICU organisa-
tional contexts, implying the desirability of further
clinical validation outside Europe. This Australian pilot
study aimed to estimate the magnitude of effect of
SmartCare/PS compared with usual weaning methods in
the absence of formalised weaning protocols. This work
has been presented in abstract form [6].
Methods
Patients
Eligible patients were those admitted to the adult ICU of
The Royal Melbourne Hospital between January and
December 2006 who required mechanical ventilation with
a volume or pressure targeted mandatory mode of venti-
lation for greater than 24 h. These modes included
synchronised intermittent mandatory ventilation (SIMV),
assist-control (A/C), or biphasic intermittent mandatory
ventilation (BIPAP) (referred as BilevelTM on Puritan
Bennett 840 ventilators, Puritan Bennett, CA, USA). No
other restrictions were placed on the use of modes prior to
randomisation once the requirement for 24 h of manda-
tory ventilation was met. Those patients who tolerated
pressure support ventilation early (within 24 h) were
excluded as this was considered an indicator of ‘‘simple
weaning’’ patients for whom successful extubation occurs
without difficulty [7].
The Institutional Review Boards of both the partici-
pating hospital and The University of Melbourne
approved the study. Informed consent was obtained from
the participant’s next of kin prior to enrolment and later
from those participants who regained competency to
consent in accordance with Victorian State law.
Study protocol
In addition to the requirement for a minimum of 24 h of
mandatory ventilation as described above, eligibility cri-
teria were: a Dra¨ger EvitaXL (Dra¨ger Medical, Lu¨beck,
Germany) ventilator with SmartCare/PS software version
1.1 available for use immediately prior to randomisation
(4 such ventilators available in a 24-bed ICU),
PEEP B 8 cmH2O, PaO2/FiO2 ratio [ 150 (mmHg) or
SaO2 C 90% with FiO2 B 0.5, plateau pressure B
30 cmH2O, haemodynamic stability (inotrope infusions
of noradrenaline or adrenaline B 16.5 lg/min, or dopa-
mine B 500 lg/min [2]), body temperature 36–39C
peripherally, stable neurological status with a Glasgow
coma score (GCS) [ 4, and no anticipated requirements
(within 2 h) for transport or surgery. The final criterion
for study entry was successful completion (maintenance
of respiratory and cardiovascular stability) of a 30-min
spontaneous breathing test using PS (maximum
20 cmH2O) to achieve VT [ 200 mL. If automatic tube
compensation was in use this was turned off prior to
selection of an appropriate PS level. If the PS test was
failed, it was repeated at the earliest discretion of the
treating clinicians. If no Dra¨ger EvitaXL ventilator was
available an otherwise eligible patient could not be ran-
domised. Patients were also excluded if suffering from
central nervous system disorders with an anticipated poor
outcome including stroke, meningitis, cardiac arrest with
neurologic sequelae, or neuromuscular disease.
Eligible patients identified as above were allocated
randomly to wean via SmartCare/PS or usual (Control)
methods according to a computer-generated block ran-
domisation (block size of 4) administered through a
sequential opaque envelope technique. In the Control
group, clinicians were instructed to wean PS and PEEP
according to usual local practice of the participating ICU
in the absence of formal guidelines. Clinicians were
instructed to wean PS as able with no constraints as to the
frequency or size of PS adjustment while maintaining the
patient in the same ‘‘respiratory zone of comfort’’ as used
by the SmartCare/PS program. As SmartCare/PS has the
potential to wean PS every 2 or 4 min, dependent on
whether a change to PS has just been made [5] it was
considered unnecessary to limit the frequency or size of
PS adjustments to PS in the Control group.
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The respiratory zone of comfort was defined as a
respiratory frequency between 12 and 30 breaths per
minute (\34 if a neurologic disorder resulting in
tachypnoea were present); VT [ 300 mL ([250 mL if
\55 kg); and etCO2 \ 55 mmHg (\65 mmHg if the
patient had a documented history of CO2 retention during
the current episode of illness). Both SmartCare/PS and
Control patients were ultimately weaned to 7 cmH2O PS
in the presence of an endotracheal tube or 5 cmH2O if a
tracheostomy was used. If necessary, PS was also
increased to maintain the respiratory zone of comfort. The
lower PS goal in tracheostomy patients was based on the
SmartCare/PS algorithm. In addition, PEEP was reduced
to 5 cmH2O in both SmartCare/PS and Control patients
prior to a 1-h monitoring period for assessment of ‘‘sep-
aration potential’’. Weaning endpoints in the Control
group (7 cmH2O PS; 5 cmH2O PEEP) were stipulated to
ensure parity with SmartCare/PS.
Weaning in the study ICU was performed by experi-
enced and relatively autonomous nurses, the majority
(70%) of whom held a graduate critical care specialty
qualification, using a 1:1 nurse-to-patient ratio maintained
over all shifts. Respiratory therapists are not employed in
the Australian context. A team of nine intensivists
directed overall patient care through twice-daily struc-
tured ICU ward rounds with an overnight on-call roster.
Reporting to these intensivists, and providing 24-h in-ICU
medical staff, were a team of 26 hospital medical officers
representing a balanced mix of senior (registrar) and
junior (resident) levels of post-graduate training.
Extubation always remained the decision of the
attending clinicians. Readiness for extubation was deter-
mined by assessment of the patient’s ability to safely
maintain a patent airway, satisfactory gas exchange and
neurological status, and respiratory and cardiovascular
parameters within normal limits. Extubation greater than
1 h after first achieving ‘‘separation potential’’ was
defined as delayed extubation, and the reason for this
delay (pathophysiologic or organisational) was recorded.
In both study groups the need to discontinue weaning was
based on the same criteria (recurrent apnoea or worsening
clinical condition as evidenced by worsening gas
exchange, persistent tachypnoea or hypoventilation war-
ranting reinstatement of mandatory ventilation).
Statistical analysis
The time to separation, defined as time in hours from
randomisation (immediately following successful com-
pletion of the 30 min spontaneous breathing PS test) to
the time of declaration of ‘‘separation potential’’ was the
primary outcome of interest as this variable was consid-
ered to be the least confounded measure of the
SmartCare/PS effect. Secondary outcomes included the
total duration of weaning (randomisation to successful
extubation), time from intubation to first extubation, time
from intubation to successful extubation, and overall
length of ICU and hospital stay.
The primary and secondary outcomes were determined
using Kaplan–Meier estimates, with deaths regarded as
censored observations. Following the intention-to-treat
principle, all randomised patients were included in these
analyses. Treatment groups were initially compared by
log-rank tests. Subsequently, multivariate Cox propor-
tional hazards modelling was performed to estimate the
adjusted effect of selected covariates on the probability of
remaining on mechanical ventilation. The Cox model
included covariates representing patient demographics,
severity of illness indices, and selected other variables
showing univariate associations (P \ 0.10) with the pri-
mary outcome. First level interactions between selected
covariates and the weaning method were explored during
model development, and the global test of Schoenfeld
residuals described by Grambsch and Therneau [8] was
used to assess the final model’s specification.
Comparison of continuous variables between groups
was performed by the Mann–Whitney test, while cate-
gorical variables were compared using the chi-squared or
Fisher’s exact tests. All P values were two-tailed with
values of \0.05 considered statistically significant. All
analyses were performed using Minitab 14 [9] or Stata
version 9.2 [10].
Results
Participants
During the 12-month trial, a total of 988 ventilated
patients were screened, of whom a total of 102 patients
were randomised and received the intended treatment (51
in each study group, Fig. 1). The most common reason for
exclusion (n = 792) was a duration of mechanical ven-
tilation with a mandatory mode for less than 24 h. Only
four patients were excluded due to the unavailability of a
Dra¨ger EvitaXL ventilator.
The characteristics and primary indication for venti-
lation of study patients are summarised in Table 1. Both
SmartCare/PS and Control groups were similar in terms of
age, gender, severity of illness, indication for mechanical
ventilation, and its duration prior to randomisation.
Study outcomes
The probability of remaining ventilated according to the
time from randomisation to first meeting criteria for
separation potential is shown in Fig. 2. The relationship
between SmartCare/PS and the primary and secondary
outcomes of the trial are summarised in Table 2.
1790
In addition to the above univariate analyses, multi-
variate Cox proportional hazards analyses was performed
with the study primary outcome, time from randomisation
to reaching the state of ‘‘separation potential’’ and
the secondary outcome, time from randomisation to
successful extubation. As shown in Table 3, the adjusted
probability of reaching separation potential was estimated
to be 31% lower with SmartCare/PS compared to Control
(95% CI, 56% lower to 9% greater). Use of SmartCare
was not associated with time to successful extubation
either alone or when adjusted for other potentially rele-
vant covariates (P = 0.57 and P = 0.69, respectively).
Notably, greater age, male gender, elevated maximum
SOFA scores and prior receipt of neuromuscular blocking
drugs were independently associated with a reduced
chance of successful extubation (Table 3).
The number of deaths prior to declaration of separa-
tion potential (2 vs. 1 patient, P = 0.4) and successful
extubation (5 vs. 0 patients, P = 0.06) was similar in both
the SmartCare/PS and Control groups. Likewise the rates
of reintubation within 48 h (5 SmartCare/PS patients vs. 6
Control patients, P = 1.0), use of non-invasive ventila-
tion post-extubation (8 vs. 6, P = 0.8), requirement for
tracheostomy (6 vs. 8, P = 0.8) or prolonged episode of
mechanical ventilation [14 days (5 vs. 7, P = 0.8) were
similar between study groups.
Compared to Control, more participants in the
SmartCare/PS group experienced a delay in extubation
[1 h (31/51 vs. 22/51 participants, P = 0.07). The most
frequent reason for delayed extubation was a low GCS
[SmartCare/PS 12 (24%) patients, Control 9 (18%)
patients] followed by respiratory failure as evidenced by
worsening chest X-ray or gas exchange [SmartCare/PS 8
(16%) patients, 3 (6%) Control patients]. Organisational
factors such as unavailability of senior staff highly
Excluded     (n = 886)
Mandatory ventilation duration <24 h (n = 792) 
Other inclusion criteria not met  (n =  52) 
Failure to randomise    (n =  18) 
No consent     (n =  14) 
Other      (n =  10) 
Randomised (n = 102) 
Control (n = 51) SmartCare/PS (n = 51) 
All ventilated patients (n = 988) 
Jan to Dec 2006 
Fig. 1 Trial diagram
Table 1 Patient characteristics
Characteristic SmartCare/PS
(n = 51)
Control
(n = 51)
Age (years)a 51 (29–68) 54 (38–65)
Ventilation prior to
randomisation (h)a
68 (40–114) 66 (42–133)
Severity of illness scoresa
APACHE II 17 (14–48) 18 (11–32)
SAPS II 38 (24–49) 41 (27–54)
Admission SOFA 6 (4–9) 6 (4–9)
SOFAmax 10 (8–12) 9 (7–12)
PaO2/FiO2 ratio
b 226 (197–297) 234 (169–283)
Male gender n (%) 36 (71) 32 (63)
Admission type n (%)
Trauma 24 (47) 24 (47)
Surgical 16 (31) 13 (26)
Medical 11 (22) 14 (27)
Indication for
ventilation, n (%)c
Trauma 24 (47) 24 (47)
Coma 10 (20) 9 (18)
Postoperative 5 (10) 4 (8)
Pneumonia 5 (10) 3 (6)
Sepsis 3 (5.5) 4 (8)
Heart failure 1 (2) 5 (10)
Other 3 (5.5) 2 (4)
APACHE Acute physiology and chronic health evaluation, SAPS
simplified acute physiology score, SOFA sequential organ failure
assessment, SOFAmax maximum organ failure score during ven-
tilation [11]
Log-rank test P = 0.3. Plot truncated at 150 h due to small num-
bers of patients beyond that point
a Median (interquartile range, IQR)
b Worst PaO2/FiO2 ratio recorded on the day of study inclusion
c Though not an exclusion criteria, no patients with chronic
obstructive pulmonary disease met the entry criteria for the study
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Fig. 2 Kaplan–Meier estimated probability of remaining venti-
lated. Log-rank test P = 0.3. Plot truncated at 150 h due to small
numbers of patients beyond that point. a Time in hours from
randomisation to the time of declaration of ‘‘separation potential’’
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experienced at intubation, as required by unit policy,
accounted for extubation delay in seven (14%) Smart-
Care/PS patients and in six (12%) Control patients. The
median time elapsed from first achievement of the sepa-
ration criteria to the clinical decision to proceed to first
extubation was 19 (IQR 5–60) hours in the SmartCare/PS
group and 31 (IQR 5–60) hours in the Control group
(P = 0.04).
Sedation administered to each trial group was simi-
lar, both prior to and after inclusion on the study
protocol (Table 4). The frequency of exposure to corti-
costeroids was also comparable between the two groups
(P = 0.5).
The median highest level of PS used was 13 cmH2O
(IQR 10–19 cmH2O) in the SmartCare/PS group and
15 cmH2O (IQR 10–15 cmH2O) in the Control group.
Compared to Control, the SmartCare/PS group had a
greater median number of PS changes (34 vs. 7 changes,
P \ 0.001). The maximum PEEP settings were similar
between SmartCare/PS (10 cmH2O, IQR 10–12 cmH20)
and Control (10 cmH2O, IQR 10–15 cmH2O).
Patient extubation occurred prior to achievement of
the criteria for separation (PS 7 cmH2O and PEEP
5 cmH2O), in 20% of the SmartCare/PS group and 39%
of Control (P = 0.03). In the SmartCare/PS group, non-
compliance with the study protocol was mainly due to a
clinical assessment of patient–SmartCare/PS incompati-
bility, such as occurred in 14% of patients where high
levels of PS were reached repeatedly due to unstable
breathing patterns, or a clinical decision to proceed to
extubation prior to reaching a declaration of separation
potential (6% of patients). In the Control group, non-
compliance was entirely due to a clinical decision to
extubate prior to a reduction of PEEP to 5 cmH2O.
Discussion
In this first Australian pilot study, the unadjusted chance
of reaching ‘‘separation potential’’ was estimated to be
21% lower (95% CI, 48% lower to 20% greater) with
SmartCare/PS compared to Control. Following adjust-
ment for age, gender, severity of illness, use of
neuromuscular blockade or use of corticosteroids, maxi-
mum blood glucose during ICU admission, and presence
of coma, the estimated probability of reaching ‘‘separa-
tion potential’’ remained 31% lower (95% CI, 56% lower
to 9% greater) with SmartCare/PS. Likewise, use of
SmartCare was not associated with a decreased time to
successful extubation using either unadjusted or adjusted
analyses.
To the present, there has been only one published large
randomised study of SmartCare/PS. In the recent study of
144 patients admitted to five European ICUs, SmartCare/
PS was demonstrated to reduce the median duration of
weaning from 5 to 3 days (P = 0.01) and the median total
duration of ventilation by 4.5 days (P = 0.003) with no
differences in ventilatory complications between the two
groups [2]. In the current Australian study the returned
upper limits of the estimated likely benefit from Smart-
Care/PS for the time to successful weaning were 70%
(unadjusted) or 43% (adjusted), with a multivariate point
estimate of effect actually unfavourable to SmartCare/PS.
Table 2 Primary and secondary outcomes
SmartCare/PS Control P value
Primary outcome
Time to ‘‘separation’’ (h)a 20 (2–40) 8 (2–43) 0.3
Secondary outcomes
Time to successful extubation (h)b 43 (6–169) 40 (14–87) 0.6
Ventilation to first extubation (h)c 119 (66–218) 128 (54–218) 0.9
Total duration of ventilation (h)d 119 (69–226) 129 (62–243) 0.9
Length of ICU stay (h)e 146 (106–286) 196 (97–293) 0.7
Length of hospital stay (h)f 445 (301–788) 532 (334–791) 0.9
Data denote estimated median (IQR) time in hours according to
Kaplan-Meier methods with Log-rank P values. Deaths were
treated as censoring events
a Time in hours from inclusion in the study to the time of decla-
ration of ‘‘separation potential’’
b Time in hours from randomisation at study commencement to
successful extubation. Denoted as primary outcome in previously
reported randomized, controlled trial of SmartCare/PS [2]
c Time in hours from commencement of ventilation in ICU to first
extubation. Time in hours from commencement of ventilation in
ICU to discontinuation from positive pressure ventilation (if sus-
tained for C24 h) for patients who required tracheostomy
d Time in hours from commencement of ventilation in ICU to
successful extubation. Time in hours from commencement of
ventilation in ICU to successful discontinuation from positive
pressure ventilation for patients who required tracheostomy
e Time in hours from ICU admission to ICU discharge
f Time in hours from hospital admission to hospital discharge
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The current Australian study showed a number of
differences in baseline patient characteristics compared to
the European study [2]. These differences included lower
median ages and SAPS II scores, a larger proportion of
trauma patients, and the absence of COPD patients. These
differences imply that SmartCare/PS may be of most use
with patients who are more difficult to wean, and further
studies are required to define the characteristics of ven-
tilated patients best suited to the application of
SmartCare/PS.
Further, in the European study the median duration of
weaning and ventilation were comparatively prolonged in
both the SmartCare/PS (wean 3.0 days, ventilation
7.5 days) and Control groups (wean 5.0 days, ventilation
12.0 days) compared to those reported in this Australian
study. In the Control group of the European study,
assessment of criteria to determine extubation readiness
was performed daily in one institution or two-to-three
times a day in the other participating ICUs [2]. In com-
parison, weaning management in the current Australian
study involved unlimited assessment of weaning and
extubation readiness performed by experienced and rela-
tively autonomous critical care nurses using a 1:1 nurse-
to-patient ratio, supported by 24-h house medical staff
and twice-daily rounds by intensivists. These organisa-
tional features are common to Australian ICUs in which
ICU nurses commonly titrate ventilation and manage
respiratory therapy according to physician-set physiologic
targets [12–14].
The lack of a clear association between SmartCare/PS
and a substantial reduction in the duration of weaning also
may have been due to locally specific weaning practices
and organisational structure of the study ICU, such that
the present study results may not necessarily be repro-
duced in other ICUs. In this regard, some evidence
suggests a shorter duration of weaning and overall ven-
tilation compared to previously reported international
norms [15, 16] in the study ICU prior to the evaluation of
the SmartCare/PS system [17].
Studies of weaning protocols conducted in ICUs with
high staffing levels, such as those present in the current
Australian hospital, may not demonstrate the same
advantage as those performed in ICUs with lower staffing
levels [18]. The ability of SmartCare/PS to effect a
reduction in the duration of ventilation may differ sub-
stantially in an ICU that does not normally provide
frequent titration of ventilation instituted by trained and
specialised medical and nursing staff.
Although randomised, this study was potentially
limited due to the difficulty of conducting a blinded
assessment of ventilatory or weaning methods, making it
possible that clinical staff may have introduced bias by
conscious or unconscious actions or decisions. No
attempt was made to measure these possible influences
on ICU weaning behaviour in the presence of the
SmartCare/PS system. However, some evidence against a
large bias of this type was provided by comparison with
the duration of ventilation previously observed in the
same Australian ICU 1 year prior to commencement of
the SmartCare/PS trial [17]. Data from that study, for the
patient subgroup who received some form of mandatory
ventilation for a minimum of 24 h prior to the com-
mencement of weaning, showed an overall duration of
mechanical ventilation (median 117 h (IQR 54–207 h)
closely comparable to those observed in the Control
group of the present study.
An important aim of SmartCare/PS is the maintenance
of each patient in a proprietary ‘‘respiratory zone of
comfort’’ by continuous monitoring and real-time inter-
ventions [5]. In the current study, a notable observation
was the substantially greater number of changes to the PS
level in the SmartCare/PS group compared to Control
patients. An assessment of any consequence of this
greater frequency of PS manipulation on a patient’s
Table 4 Use of sedation and neuromuscular blockade
Before inclusion P valuea After inclusion P valuea
SmartCare/PS Control SmartCare/PS Control
Propofol (mg) 1,665 (523–6,485) 1,630 (400–5,078) 0.8 1,515 (35–3,783) 705 (25–4,579) 0.7
Midazolam (mg) 156 (39–418) 166 (55–399) 0.8 0 (0–25) 0 (0–25) 0.3
Morphine (mg) 143 (44–407) 165 (48–387) 0.9 0 (0–25) 0 (0–7) 0.5
Fentanyl (lg)b 0 (0–0) 0 (0–0) 0.5 0 (0–0) 0 (0–0) 0.9
Vecuronium (mg) 10 (0–30) 10 (0–32) 0.8 0 (0–0) 0 (0–0) 0.9
Data denote median (IQR) of total quantity of each drug adminis-
tered in ICU divided according to time of randomisation
Drugs used in\10 patients overall included diazepam, olanzapine,
clonidine, pethidine, fentanyl, ketamine, dexemetomidine, halo-
peridol, and rocuronium
a Difference in total dose calculated using Mann-Whitney test.
Analysis of sedation administered per hour of ventilation produced
similar results (data not shown)
b Maximum dose of Fentanyl used before study inclusion was
1,028 lg in the SmartCare/PS group (920 lg after inclusion) and
1,030 lg in Control (555 lg after inclusion)
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experience of SmartCare/PS weaning, relative to more
conventional methods, has not yet been reported.
Conclusion
This pilot study represented the first randomised evalua-
tion of the SmartCare/PS system in an Australian ICU. In
this clinical context, SmartCare/PS did not reduce sub-
stantially the duration of weaning, in marked contrast to
its previously demonstrated success in Europe. The per-
formance of SmartCare/PS in this Australian study
showed no obvious advantage over existing weaning
methods, which comprised frequent assessment of
weaning readiness and titration of ventilatory support
performed by registered nurses qualified and experienced
in ventilatory management, in collaboration with trained
medical specialists working in a closed ICU model. A
large multi-centre study may be required to more clearly
estimate the magnitude of any advantage of SmartCare/PS
on the duration of weaning from mechanical ventilation in
Australian ICUs, where experienced critical care specialty
nurses manage ventilated patients using a 1:1 nurse-to-
patient ratio.
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